|Dr. Eugene P. Kennedy M.D., FACS||Chief Medical Officer||619.64k||N/A||1969|
|Mr. Carl W. Langren||CFO & Principal Accounting Officer||N/A||N/A||1955|
|Ms. Lisa Miller||Director of Investor Relations||N/A||N/A||N/A|
|Brad J. Powers||Gen. Counsel||N/A||N/A||N/A|
|Mr. Mario Mautino Ph.D.||Sr. VP of Drug Discovery & Intellectual Property Officer||N/A||N/A||1966|
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
NewLink Genetics Corporation’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 7; Compensation: 8.